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ATM is mutated in the human genetic disorder ataxia
telangiectasia, which is characterized by ataxia, im-
mune defects, and cancer predisposition. Cells that lack
ATM exhibit delayed up-regulation of p53 in response to
ionizing radiation. Serine 15 of p53 is phosphorylated in
vivo in response to ionizing radiation, and antibodies to
ATM immunoprecipitate a protein kinase activity that,
in the presence of manganese, phosphorylates p53 at
serine 15. Immunoprecipitates of ATM also phosphoryl-
ate PHAS-I in a manganese-dependent manner. Here we
have purified ATM from human cells using nine chro-
matographic steps. Highly purified ATM phosphoryl-
ated PHAS-I, the 32-kDa subunit of RPA, serine 15 of p53,
and Chk2 in vitro. The majority of the ATM phosphoryl-
ation sites in Chk2 were located in the amino-terminal
57 amino acids. In each case, phosphorylation was
strictly dependent on manganese. ATM protein kinase
activity was inhibited by wortmannin with an IC50 of
approximately 100 nM. Phosphorylation of RPA, but not
p53, Chk2, or PHAS-I, was stimulated by DNA. The re-
lated protein, DNA-dependent protein kinase catalytic
subunit, also phosphorylated PHAS-I, RPA, and Chk2 in
the presence of manganese, suggesting that the require-
ment for manganese is a characteristic of this class of
enzyme.
Ataxia telangiectasia is a human genetic disorder character-
ized by ataxia, immunodeficiency, cell cycle checkpoint defects,
and predisposition to cancer (1–3). The gene that is mutated in
this disorder, ATM,1 encodes a nuclear polypeptide of approx-
imately 350 kDa, which shares amino acid homology in its
COOH terminus with the phosphatidylinositol-3 (PI-3) kinase
family of proteins (4). Other members of this family include the
catalytic subunit of DNA-dependent protein kinase (DNA-
PKcs), FRAP, ATR, and the yeast gene products Mec-1, Tel-1,
and Rad3 (for review, see Refs. 5 and 6). Highly purified DNA-
PKcs has weak inherent DNA-stimulated serine/threonine pro-
tein kinase activity that is enhanced by interaction with DNA-
bound Ku (7–12). DNA-PKcs does not have PI-3 kinase activity
(13), and it is likely that, like DNA-PK, ATM also behaves as a
serine/threonine protein kinase. Indeed, several reports have
shown that immunoprecipitates of ATM from whole cells have
serine/threonine protein kinase activity toward PHAS-I and
p53 in vitro (14, 15). In immunoprecipitation assays, ATM
protein kinase activity was absolutely dependent on the pres-
ence of manganese, and activity toward p53 and PHAS-I was
not stimulated by DNA (14, 15). In contrast, others have re-
ported that immunoprecipitated ATM has DNA-dependent ki-
nase activity toward the 32-kDa subunit of single-stranded
DNA-binding protein, RPA (16). A recent report has shown
that, in crude extracts, ATM binds to DNA that has been
damaged by irradiation with x-rays (17). These sometimes con-
flicting results underscore the need for biochemical character-
ization of ATM. Although recombinant ATM protein has been
expressed in baculovirus (18, 19), the very low protein yield has
made direct biochemical study very difficult.
Cells that lack ATM are defective in their ability to activate
DNA damage response pathways that result in cell cycle arrest
at both G1/S and G2/M. ATM acts upstream of p53 and is
required for the activation of p53 and the subsequent up-
regulation of the cyclin-dependent kinase inhibitor, p21 (for
review, see Refs. 1–3). In addition, ATM is required for Chk2-
dependent cell cycle arrest at G2/M (20), and Chk2 is phospho-
rylated in vivo in an ATM-dependent manner in response to
ionizing radiation (20, 21). Recombinant ATM (18, 19) and
immunoprecipitates of ATM from DNA-damaged cells (14, 15)
phosphorylate p53 on serine 15, and ATM can interact directly
with p53 (22). Serine 15 of p53 is phosphorylated in vivo in
response to ionizing radiation (23), and phosphorylation at
serine 15 plays an important role in the ionizing radiation-
induced damage response pathway (for reviewed, see Refs. 24
and 25). However, the precise role of ATM in the activation of
p53 remains to be determined. Serine 15 of p53, which occurs in
the amino acid sequence PLSQE is also phosphorylated, in
vitro, by DNA-PK (26), suggesting that ATM and DNA-PK
recognize similar sequences in their target proteins.
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Here we describe the purification of ATM from normal hu-
man tissue. The final protein fraction contains a polypeptide of
approximately 350 kDa which cross-reacts with various anti-
bodies to ATM but not to DNA-PKcs. The ATM-containing
fraction phosphorylates serine 15 of p53, Chk2, the 32-kDa
subunit of RPA, and PHAS-I in a strictly manganese-depend-
ent manner. The protein kinase activity of purified ATM to-
ward p53, PHAS-I, and Chk2 was not stimulated by double-
stranded DNA or by Ku. Phosphorylation of RPA was
stimulated by calf thymus DNA and calf thymus DNA in the
presence of M13 single-stranded circular plasmid DNA, but not
by irradiated plasmid DNA. We also show that the related
protein, DNA-PKcs, is active in the presence of manganese in
the absence of Ku, suggesting that a requirement for manga-
nese may be characteristic of the PI-3 kinase family of
enzymes.
EXPERIMENTAL PROCEDURES
Protein Purification—ATM was purified from human placenta fol-
lowing a similar procedure to that described previously for DNA-PKcs
and Ku (9). All steps utilizing low pressure chromatography were per-
formed at 4 °C. Chromatographic steps using the Biologic Protein Pu-
rification system (Bio-Rad) were performed at room temperature. All
buffers (except buffer E, below) contained 0.2 mM phenylmethylsulfonyl
fluoride, 0.1 mM benzamidine, 1 mg/ml pepstatin, and 0.1 mM DTT. The
presence of ATM and DNA-PKcs was monitored at all stages of purifi-
cation by Western blotting using a rabbit polyclonal antibody to ATM,
4BA (22), or a rabbit polyclonal antibody, DPK1 to DNA-PKcs (8).
Antibodies to the amino-terminal, Rad3 and carboxyl-terminal domains
of ATM (27) were used in preliminary studies.
The initial stages of purification were similar to those described
previously for the purification of DNA-PKcs and Ku (9). Human pla-
centa was obtained from the Foothills Hospital, Calgary, in accordance
with the safety and ethical requirements of the university. Freshly
obtained human placenta was homogenized in buffer containing 0.5 M
salt buffer and 10 mM magnesium chloride as described previously (9),
and ATM was precipitated by the addition of ammonium sulfate to 40%
saturation. After dialysis into buffer B (50 mM Tris-HCl, pH 8, 5%
glycerol, 0.2 mM EDTA) containing 100 mM KCl, the sample was applied
to a 5 3 30-cm column of DEAE-Fast Flow Sepharose (Amersham
Pharmacia Biotech) equilibrated in the same buffer and eluted with
buffer B containing 1 M KCl. In preliminary preparations, the protein
sample was dialyzed into buffer B containing 100 mM KCl and applied
to a 5 3 15-cm column of SP-Fast Flow Sepharose (Amersham Phar-
macia Biotech). However, subsequently, this step was replaced by a 5 3
15-cm column of phenyl-Sepharose, Fast Flow (Amersham Pharmacia
Biotech), equilibrated in buffer B containing 1 M KCl. ATM was eluted
with buffer B containing 50 mM KCl. This column provided better yields
of ATM protein than the SP-Sepharose column because of higher bind-
ing capacity for ATM. Also, ATM was separated from the majority of the
DNA-PK because under these conditions, DNA-PKcs and Ku70/80 did
not bind to the phenyl-Sepharose column. The ATM-containing frac-
tions from the phenyl-Sepharose column were dialyzed into buffer B
containing 100 mM KCl, applied to a 5 3 5-cm column of MacroPrep
DEAE (Bio-Rad), and eluted with buffer B containing 100 mM KCl and
FIG. 1. Panel A, silver-stained 10% SDS-polyacrylamide gel of fractions from nickel chelation column. ATM was applied to a 5-ml HiTrap
chelation Sepharose column as described under “Experimental Procedures.” 10-ml aliquots of fractions 1–26 (eluted with a 75-min linear gradient
of 0–150 mM ammonium chloride and 0–150 mM imidazole in buffer containing 500 mM NaCl) were run on 10% SDS-acrylamide gels and silver
stained. P represents the precolumn sample, and F is the flow-through fraction. The positions of molecular mass markers are shown on the left.
The arrows indicate the presence of two polypeptides of approximately 300 and 350 kDa in the ATM-containing fractions. Panel B, Western blot
for fractions from nickel chelation column. 10 ml of the fractions shown in panel A were analyzed on 8% SDS-polyacrylamide gels, transferred to
nitrocellulose, and probed with antibody 4BA to ATM. No cross-reaction with antibodies to DNA-PKcs was observed (data not shown). The positions
of molecular mass markers are shown on the left. Panel C, protein kinase activity in fractions from nickel chelation column. 3 ml of the precolumn
(P), flow-through (F), and fractions 3, 5, 7, 9, 11, and 13 from the nickel chelation column (panel A) were incubated with PHAS-I (0.25 mg) under
assay conditions in the presence of 10 mM manganese chloride. Fraction 9 was also assayed in the presence of 10 mM magnesium chloride (9*), as
described under “Experimental Procedures.” The corresponding autoradiogram is shown. Panel D, silver stain of concentrated ATM from the last
Mono Q column. Fractions 3–15 from the nickel chelation column were pooled and applied to a Mono Q HR5/5 column equilibrated in buffer B (100
mM KCl plus 0.02% Tween 20). The column was eluted as described under “Experimental Procedures.” Too little ATM was present in these fractions
to be detected by silver stain, therefore ATM-containing fractions were identified by Western blot, and peak fractions were pooled and concentrated
using a Centricon microconcentrator. The final yield of ATM was 500 ml. 15 ml of purified ATM was analyzed by silver staining of a 10%
SDS-polyacrylamide gel (lane 1). Known concentrations of DNA-PKcs were included to estimate the protein concentration. Lane 2 contained sample
buffer alone; lanes 3–6 contained 5, 10, 20, or 50 ng of DNA-PKcs, respectively.
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100 mM magnesium chloride. A similar step involving elution of DEAE-
anion exchange resin using magnesium chloride was used for the puri-
fication of DNA-PKcs and Ku from HeLa cells (28) and placenta (9).
Fractions containing ATM were then dialyzed into buffer B containing
100 mM KCl and passed over single-stranded DNA-cellulose (Sigma),
either in batch mode or by column chromatography (1.5 3 4-cm col-
umn). Unlike DNA-PKcs and Ku, in our hands, ATM did not bind to
either single-stranded DNA-cellulose or double-stranded DNA-cellu-
lose. ATM from the flow-through fractions of the DNA-cellulose column
was then applied to a 5-ml heparin HiTrap column (Amersham Phar-
macia Biotech), equilibrated in buffer B containing 100 mM KCl and
0.02% (v/v) Tween 20. This and all subsequent steps were performed on
a Biologic Protein Purification system. ATM was eluted with a linear
gradient of buffer B containing 100 mM KCl and 0.02% Tween 20, to
buffer B containing 1M KCl and 0.02% Tween 20 over 75 min. 1-ml
fractions were collected. ATM eluted at approximately 200 mM KCl,
whereas DNA-PKcs applied to the same column under the same condi-
tions eluted at approximately 300–400 mM KCl. ATM-containing frac-
tions from the heparin HiTrap column were pooled and dialyzed into
buffer C (10 mM sodium phosphate, 50 mM KCl, 5% glycerol, pH 7.2).
The sample was applied to an Econo-Pac hydroxyapatite cartridge
(Bio-Rad) at a flow rate of 0.7 ml/min. The column was washed with
buffer C before applying a 32-ml linear gradient of increasing buffer D
(400 mM sodium phosphate, 50 mM KCl, 5% glycerol, pH 6.8). ATM
eluted at approximately 20% buffer D, corresponding to approximately
90 mM sodium phosphate. Fractions containing ATM were pooled and
dialyzed into buffer B containing 100 mM KCl and 0.02% Tween 20 and
applied to Mono Q HR5/5 fast protein liquid chromatography column
that had been equilibrated in the same buffer. Bound proteins were
eluted with a linear gradient of buffer B containing 100 mM KCl, 0.02%
Tween 20, and MgCl2 at a flow rate of 1 ml/min. The magnesium
concentration was increased at 1 mM/min. ATM eluted off the Mono Q
column between 22 and 30 mM MgCl2. In preliminary preparations,
ATM-containing fractions off the Mono Q column were applied to ATP-
Sepharose, gamma-phosphate linked (Upstate Biotechnology Inc.) that
had been equilibrated in buffer E (25 mM Hepes, pH 7.5, 1 mM DTT, 60
mM MgCl2, 0.5 mM phenylmethylsulfonyl fluoride) containing 150 mM
NaCl and eluted with buffer E containing 1M NaCl. In subsequent
preparations ATM from the Mono Q step was dialyzed into buffer F (50
mM Tris-HCl, pH 8.0, 5% glycerol, without EDTA) containing 100 mM
NaCl and applied to a 5-ml HiTrap chelation Sepharose column (Am-
ersham Pharmacia Biotech) that had been loaded with nickel sulfate
according to the manufacturer’s recommendations. The column was
equilibrated in buffer F containing 100 mM NaCl and after sample
loading was washed sequentially with 15 ml of buffer F containing 100
mM NaCl followed by 15 ml of buffer F containing 500 mM NaCl. ATM
was eluted with a linear gradient of buffer F containing 500 mM NaCl
to buffer F containing 500 mM NaCl, 150 mM imidazole, and 150 mM
ammonium chloride at 1.5 mM imidazole and ammonium chloride per
minute. ATM-containing fractions were dialyzed and applied onto a
Mono Q HR5/5 column that had been equilibrated in buffer B contain-
ing 100 KCl and 0.02% Tween-20 and eluted with a gradient of buffer B
containing 1M KCl and 0.02% Tween 20. ATM-containing fractions were
desalted and concentrated on a Centricon 100 microconcentrator (Ami-
con), washed with buffer B containing 100 mM KCl, 0.02% Tween 20, 0.5
mM phenylmethylsulfonyl fluoride, 1 mM DTT, and stored in aliquots at
280 °C.
Protein Kinase Assays—ATM kinase assays contained 25 mM Tris-
HCl, pH 8, 50 mM KCl, 5% glycerol, 0.5 mM DTT, 5 mCi of [g-32P]ATP,
10 mM cold ATP, 10 mM MnCl2, 0.25–0.5 mg of PHAS-I (Stratagene) or
other substrate as indicated, and 2–4 ng of purified ATM. The reactions
were incubated at 30 °C for 30 min, stopped with SDS sample buffer,
and analyzed by SDS-polyacrylamide gel electrophoresis on 15% acryl-
amide gels. Gels were stained with Coomassie Blue, destained exten-
sively, dried, and exposed to Fuji x-ray film with intensifying screen at
280 °C.
DNA-PK was purified and assayed as described previously (9, 40).
Sonicated calf thymus DNA was prepared as described previously (28).
Irradiated pUC18 plasmid DNA was prepared as described previously
(29). Single-stranded M13 circular plasmid DNA was obtained from Life
Technologies, Inc.
Amino acids 1–40 of p53 were expressed in bacteria as a GST fusion
protein, purified over glutathione Sepharose, and dialyzed into buffer B
containing 100 mM KCl before use. The amino-terminal 222 amino acids
of human Chk2 were expressed in pGEX-5X-1 as a GST fusion, and
protein was expressed and purified as for p53. A GST fusion protein
expressing amino acids 58–222 of Chk2 (Chk2(D57N)) was created by
deleting the first 174 base pairs from the Chk2 coding sequence. The
protein was expressed and purified as above. A plasmid expressing
His-tagged RPA32 and 14-kDa subunits was a kind gift from Dr. Aled
Edwards (Ontario Cancer Institute).
Western Blotting—ATM and DNA-PKcs were analyzed on 8% SDS-
acrylamide gels, as described previously (9). The antibodies used for
detection of ATM were a rabbit polyclonal to the Rad3 domain of ATM,
4BA (22). A rabbit polyclonal antibody to amino acids 819–894 of ATM
(Oncogene Scientific, ATM Ab-3, PC116) was also used. The p53 mono-
clonal antibody, DO1, was obtained from Oncogene Scientific. The rab-
bit polyclonal antibody to DNA-PKcs (DPK1) was as described previ-
ously (8). A rabbit polyclonal antibody specific for serine 15 of p53 was
as described previously (22).
RESULTS
The cDNA sequence of ATM predicts a polypeptide of approx-
imately 350 kDa with amino acid similarity to the PI-3 kinase
family of proteins in the carboxyl-terminal domain. Attempts to
express active ATM in baculovirus have not been very success-
ful, probably because of the large size of the protein. To date,
most of the information regarding the properties of ATM has
been obtained from immunoprecipitates. Because immunopre-
cipitates may contain contaminating or interacting proteins
and because antibody binding could interfere with the biochem-
ical properties of the putative protein, we considered it impor-
tant to purify the protein by biochemical means to characterize
the biochemical properties of ATM fully. Here we have used
conventional biochemical techniques to purify ATM from hu-
man placenta. We previously described a procedure to purify
the related protein DNA-PK from the same source (9) and
therefore used these procedures as a guide to purify ATM.
Because immunoprecipitates of ATM phosphorylate p53 on
serine 15 and because the same residue is phosphorylated by
DNA-PK in vitro, it was important to separate DNA-PK from
ATM completely during the purification procedure.
The presence of ATM and DNA-PKcs was determined by
Western blot at each stage of the purification, and fractions
containing ATM were judiciously pooled. ATM was precipitated
by 40% ammonium sulfate and bound to DEAE-Sepharose
anion exchange matrix. DNA-PKcs and Ku proteins were also
found in the same fractions. However, most of the DNA-PKcs
and Ku was removed from ATM by binding to phenyl-Sepha-
rose in buffer B containing 1M KCl. Under these conditions,
most of the DNA-PKcs and Ku did not bind to the column,
whereas ATM bound and was eluted with buffer B containing
50 mM salt. Partially purified ATM that was eluted from DEAE
by magnesium-containing buffer did not bind to either double-
stranded or single-stranded DNA-cellulose resins. In contrast,
DNA-PKcs and Ku bound tightly to both resins, again provid-
ing a means for separation of DNA-PK from ATM. ATM and
TABLE I
Protein yields during purification of ATM
ATM was purified as described under “Experimental Procedures,”
starting with approximately 300 g of placenta. Protein concentrations
for steps up to the first Mono Q FPLC column were determined using
the Bio-Rad protein assay and bovine serum albumin as standard. The
concentration of ATM in the final step was estimated by comparison
with known amounts of DNA-PKcs protein on silver-stained gels (see
Fig. 1B). ND, not determined.
Purification step Total protein
mg
Ammonium sulfate precipitation 4179
DEAE 1 M eluate 3349
Phenyl-Sepharose, 50 mM eluate 92
DEAE, magnesium eluate 40
DNA-cellulose flow 22
Heparin HiTrap pooled fractions 8
Hydroxyapatite, pooled fractions 1.2
Mono Q, magnesium elution, pooled fractions 0.1
Nickel chelation HiTrap, pooled fractions ND
Mono Q, salt elution, pooled fractions 0.001
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DNA-PKcs also eluted at different salt conditions on heparin
HiTrap chromatography, again providing for maximum sepa-
ration of the two proteins.
In preliminary preparations, the final step of the purification
of ATM was binding to ATP-Sepharose (gamma-phosphate
linked). However, very little ATM was recovered from this
column, and despite various elution strategies, the majority of
the protein remained bound to the ATP-Sepharose beads.2 Pre-
liminary experiments indicated that ATM bound to chelation
Sepharose resin that had been loaded with nickel, copper, or
zinc but not with magnesium or manganese.3 Chelation Sepha-
rose was therefore used in place of the ATP-Sepharose column.
ATM-containing fractions were applied to a nickel-loaded Hi-
Trap chelation Sepharose column and eluted with a gradient of
ammonium chloride and imidazole in buffer B containing 500
mM NaCl. Two polypeptides of approximately 350 and 300 kDa
were observed on silver-stained SDS-polyacrylamide gels (Fig.
1A, upper arrow and lower arrow, respectively). ATM was
detected by Western blotting in fractions 3–21 (Fig. 1B). The
upper band in the Western blot (Fig. 1B) comigrated with the
upper band in the silver stained gel (Fig. 1A, upper arrow). The
lower band in the Western blot ran slightly ahead of the 200-
kDa marker and is likely a breakdown product of ATM. The
ATM-containing fractions were assayed for their ability to
phosphorylate PHAS-I, a substrate that has been shown pre-
viously to be phosphorylated by immunoprecipitates of ATM in
the presence of manganese (14, 15). Manganese-dependent
phosphorylation of PHAS-I was observed in the ATM-contain-
ing fractions (Fig. 1C). ATM-containing fractions were pooled
and applied to a Mono Q fast protein liquid chromatography
column and eluted with a salt gradient. The ATM-containing
fractions were concentrated and desalted as described under
“Experimental Procedures.” The final yield of ATM was esti-
mated by comparison with known amounts of DNA-PKcs on
silver-stained gels (Fig. 1D). The major band in the sample
migrated at 350 kDa, coincident with ATM in Western blots.
The polypeptide at approximately 300 kDa comigrated with the
ATM breakdown product on Western blot. We estimate that
approximately 2 mg of highly purified ATM was obtained from
one placenta (Table I). In contrast, up to 500 mg of DNA-PKcs
and 1 mg of Ku70/80 heterodimer could be purified from the
same amount of starting material, suggesting that ATM is
present in far less abundance than DNA-PKcs in human tis-
sues. In preliminary studies, we examined rat liver and bovine
testis as potential sources of ATM; however, poor antibody
recognition and/or low abundance made purification of ATM
from non-human sources impractical.4
The highly purified ATM fraction was next assayed for its
ability to phosphorylate a number of protein substrates in the
presence of either magnesium or manganese as metal ion. ATM
activity was also assayed in the presence of the PI-3 kinase
inhibitor, wortmannin. Because the kinase activity of the re-
lated protein, DNA-PKcs, is modulated by DNA and the
Ku70/80 heterodimer, ATM was also assayed in the presence of
both sonicated calf thymus DNA and Ku. Phosphorylation of
PHAS-I was completely dependent on the presence of manga-
nese (Fig. 2A) and was inhibited by wortmannin (Fig. 2A, lane
3) with an IC50 of approximately 100 nM (data not shown). The
addition of sheared calf thymus DNA did not stimulate PHAS
phosphorylation (Fig. 2A, lane 5). Phosphorylation of PHAS
was also not affected by the addition of purified Ku het-
erodimer, in the presence or absence of DNA (Fig. 2B).
Serine 15 of p53 is phosphorylated in vivo in response to
ionizing radiation (23). Further, previous studies indicated
that immunoprecipitated ATM can, in the presence of manga-
nese, phosphorylate p53 on serine 15 (14, 15, 22). We therefore
examined whether purified ATM could also phosphorylate p53
in vitro. Phosphorylation of p53 by highly purified ATM was
absolutely dependent on manganese, was inhibited by wort-
2 D. W. Chan, P. Douglas, and S. P. Lees-Miller, unpublished
observations.
3 W. Block and S. P. Lees-Miller, unpublished observations. 4 W. Truong and S. P. Lees-Miller, unpublished observations.
FIG. 2. Phosphorylation of PHAS-I
by purified ATM. Panel A, approxi-
mately 2 ng of ATM was assayed for phos-
phorylation of PHAS-I (0.25 mg/reaction)
in the presence of 10 mM MnCl2 (lanes 1–3
and 5) or 10 mM MgCl2 (lane 4). Wortman-
nin was added to the sample in lane 3 to
0.5 mM. Sonicated calf thymus DNA was
added to the sample in lane 5 to a final
concentration of 10 mg/ml. Lane 1 con-
tained PHAS-I, manganese, and ATP but
not ATM. Samples were analyzed on 15%
SDS-polyacrylamide gels and exposed to
x-ray film overnight at 280 °C with inten-
sifying screens. Panel B, ATM-mediated
phosphorylation of PHAS-I was assayed
in the presence of 10 mM manganese chlo-
ride, with no other additions (lane 1), with
the addition of 10 mg/ml calf thymus DNA
(lane 2), or with 20 ng of Ku in the ab-
sence (lane 3) or presence (lane 4) of 10
mg/ml calf thymus DNA. Also shown is Ku
assayed in the absence of added ATM,
both in the absence (lane 5) and presence
(lane 6) of added DNA.
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mannin, and was not stimulated by the addition of sheared
DNA (Fig. 3A). Western blotting with a phosphospecific anti-
body to serine 15 of p53 indicated that serine 15 was phospho-
rylated (data not shown).
The serine/threonine protein kinase Chk2 is phosphorylated
in vivo in an ATM-dependent manner in response to ionizing
radiation (20, 21). Because ATM phosphorylates p53 at serine
15 in the context PLSQE, this suggests that, like DNA-PK,
ATM protein kinase also recognizes serines that are followed
by glutamine. Human Chk2 contains several putative ATM
phosphorylation sites at amino acids 19, 26, 28, 33, 35, 50, 68,
357, and 432. The amino-terminal 222 amino acids of Chk2
were expressed as a GST construct and assayed for phospho-
rylation by purified ATM. Recombinant Chk2 was phosphoryl-
ated by ATM in a manganese-dependent manner (Fig. 3B).
Phosphorylation was inhibited by wortmannin and was not
stimulated by the addition of sonicated calf thymus DNA (Fig.
3B, lanes 3 and 5, respectively). Because the majority of the
potential ATM phosphorylation sites are located in the amino-
terminal 60 amino acids, we tested the ability of purified ATM
to phosphorylate a GST construct in which the amino-terminal
57 amino acids of Chk2 had been deleted (Chk2(D57N)). ATM
phosphorylated Chk2(D57N) weakly, consistent with the major
in vitro phosphorylation sites in Chk2 being located between
amino acids 1 and 57 (Fig. 3C).
A previous study has shown that immunoprecipitates of
ATM phosphorylate the 32-kDa subunit of RPA in a DNA-de-
pendent manner (16). RPA is also phosphorylated by DNA-PK
at amino-terminal SQ sites (32, 33), and the yeast homolog of
ATM, Mec-1, is required for the phosphorylation of RPA in
yeast (34). We therefore assayed for the ability of purified ATM
to phosphorylate both recombinant RPA (32- and 14-kDa sub-
units) and heterotrimeric RPA (32-, 14-, and 70-kDa subunits).
The 32-kDa subunit of RPA (RPA32) was phosphorylated in the
context of the recombinant protein, and phosphorylation was
modestly, but consistently stimulated by the addition of
sheared calf thymus DNA (Fig. 4A). Phosphorylation was man-
ganese-dependent and was inhibited by wortmannin (Fig. 4A).
In contrast, the 32-kDa subunit of RPA in the context of the
purified heterotrimeric protein was less strongly phosphoryl-
ated by purified ATM under the conditions used in this assay
(Fig. 4B). RPA binds to single-stranded DNA and is required
for DNA replication in vivo (for review, see Ref. 35). RPA is also
required for nucleotide excision repair and enhances the bind-
ing of XPA protein to UV-damaged DNA (36). Gately et al. (16)
have reported that phosphorylation of RPA32 by immunopre-
cipitates of ATM was stimulated by single-stranded closed cir-
cular DNA (M13 DNA) in the presence of sheared double-
stranded DNA (calf thymus DNA). A recent report has shown
that ATM binds preferentially to irradiation-damaged DNA-
cellulose compared with undamaged DNA-cellulose and that
this interaction does not require DNA-PKcs or Ku (17). Taking
all of these findings into account, we postulated that RPA
might act as a DNA-targeting subunit for purified ATM, in a
manner similar to targeting of DNA-PKcs to DNA ends by the
Ku heterodimer. RPA heterotrimer was therefore incubated
with purified ATM either in the absence of DNA (Fig. 4C, lane
1) or in the presence of plasmid DNA that had been irradiated
with 0, 10, 25, 50, or 100 Gy (Fig. 4C, lanes 2–6, respectively).
The concentration of DNA used was shown previously to give
maximum activation of DNA-PK (29). No stimulation of ATM
activity toward RPA heterotrimer was observed (Fig. 4C). The
FIG. 3. Phosphorylation of p53 and
Chk2 by purified ATM. Approximately 2
ng of purified ATM was incubated with 0.5
mg of either recombinant GST-tagged p53
(amino acids 1–40) (panel A), recombinant
GST-tagged Chk2 (amino acids 1–222) (pan-
el B), or recombinant GST-tagged Chk2 that
lacks the amino-terminal 57 amino acids,
(Chk2(D57N)) (panel C). Assay conditions
were as described under “Experimental Pro-
cedures.” For panels A and B, lane 1 in each
panel contained protein substrate but no
ATM; lane 2 contained ATM plus protein
substrate in the presence of 10 mM manga-
nese chloride; lane 3, as lane 2 but with 0.5
mM wortmannin; lane 4, as lane 2 but with
10 mM magnesium chloride instead of man-
ganese chloride; lane 5, as lane 2 but with 10
mg/ml sonicated calf thymus DNA. Panel C,
Chk2(1–222) (lanes 1 and 3) or Chk2(D57N)
(lanes 2 and 4) was incubated under assay
conditions as described under “Experimen-
tal Procedures” either without (lanes 1 and
2) or with (lanes 3 and 4) 2 ng of purified
ATM. The positions of Chk2(1–222) and
Chk2(D57N) are indicated on the right.
Lane 5 contained ATM alone. The corre-
sponding autoradiogram is shown.
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presence of irradiated plasmid DNA up to 50 mg/ml did not
increase the phosphorylation of either heterotrimeric RPA or
PHAS-I (data not shown). We also examined phosphorylation
of heterotrimeric RPA in the presence of M13 DNA under the
conditions used by Gately et al. (16). Our results concur with
their findings in that addition of M13 single-stranded closed
circular DNA in the presence of sheared DNA greatly stimu-
lated the phosphorylation of heterotrimeric RPA (Fig. 4C, lane
8). M13 without calf thymus DNA did not stimulate phospho-
rylation of RPA by ATM (data not shown), whereas the addition
of calf thymus DNA had a modest effect on phosphorylation of
RPA (Fig. 4C, lane 7). The phosphorylation of PHAS-I was not
affected by the presence of M13 DNA in the absence or presence
of calf thymus (data not shown), suggesting that these effects
are specific for RPA.
Other studies have shown that phosphorylation of p53 and
PHAS-I by immunoprecipitates of ATM requires manganese
(14, 15). Here we have shown that the kinase activity of puri-
fied ATM toward PHAS-I, Chk2, RPA, and p53 also requires
manganese. We have reported that manganese does not sup-
port DNA-dependent kinase activity toward hsp90 (28), sug-
gesting that the requirement for different metal ions may be a
distinguishing feature between ATM and DNA-PK. As control
experiments for the above studies, we therefore incubated
highly purified DNA-PKcs or DNA-PKcs plus Ku with several
protein substrates in the presence and absence of DNA, man-
ganese, and magnesium. In the presence of magnesium, and at
physiological salt concentration, DNA-PKcs (in the absence of
Ku) had very little kinase activity toward PHAS-I, p53, Chk2,
or RPA32 (Fig. 5, lane 1 in each panel). Upon longer exposures,
DNA-dependent phosphorylation was observed in each case;
however, in each case the addition of highly purified Ku het-
erotrimer greatly enhanced the phosphorylation of all sub-
strates tested (Fig. 5, lane 3 in each panel). However, in the
presence of manganese, PHAS-I, Chk2, and RPA32 were highly
phosphorylated by DNA-PKcs in the absence of Ku (Fig. 5, lane
5) and phosphorylation was partially DNA-dependent (Fig. 5,
lanes 5–8). In contrast, a construct containing amino acids
1–40 of p53 was phosphorylated poorly by DNA-PKcs in the
presence of manganese, regardless of the presence of Ku or
DNA (Fig. 5).
DISCUSSION
We have developed a biochemical procedure to purify ATM
from normal human tissue. The final product is highly enriched
for ATM; however, we cannot exclude the possibility that trace
amounts of contaminating proteins remain in the sample. It
was not possible to purify ATM further because of the ex-
tremely low yields of protein obtained. We show that highly
purified ATM has manganese-dependent serine/threonine pro-
tein kinase activity toward p53, RPA 32-kDa subunit, and
PHAS-I, consistent with the reported properties of immunopre-
cipitated ATM (14–16). Like DNA-PK, ATM phosphorylates
p53 on serine 15 in an “SQ motif,” suggesting that both protein
kinases have similar recognition motifs for phosphorylation.
We also show that purified ATM phosphorylates Chk2, which is
phosphorylated in vivo in an ATM-dependent manner (20, 21).
Moreover, we show that the majority of the in vitro phospho-
rylation sites in the amino-terminal 222 amino acids of Chk2
are located in the first 57 amino acids, a region that contains
six potential ATM phosphorylation sites at serines 19, 28, 33,
35, and 50 and threonine 26.
Purified ATM kinase activity was inhibited by wortmannin
with an IC50 of approximately 100 nM, which is similar to that
FIG. 4. Phosphorylation of RPA by
purified ATM. Panel A, 0.5 mg of recom-
binant His-tagged RPA (32- and 14-kDa
subunits) was incubated either alone
(lane 1) or with ATM (lanes 2–5) in the
presence of 10 mM manganese chloride
(lanes 1–3 and 5) or 10 mM magnesium
chloride (lane 4), as described in Fig. 3A.
Wortmannin was added (to 0.5 mM final
concentration) to the sample in lane 3.
Panel B, lanes were exactly as in panel A,
except they contained 0.5 mg of purified
heterotrimeric RPA instead of recombi-
nant RPA32/14. The position of migration
of RPA70 is shown. No phosphorylation of
RPA14 was observed. Panel C, 0.5 mg of
purified RPA heterotrimer was incubated
with ATM (2 ng) in the presence of 10 mM
manganese chloride in the presence of
various types of DNA (final concentration
0.5 mg/ml). Lane 2, closed circular plasmid
DNA; lane 3, plasmid DNA irradiated at
10 Gy; lane 4, plasmid DNA irradiated at
25 Gy; lane 5, plasmid DNA irradiated at
50 Gy; and lane 6, plasmid DNA irradi-
ated at 100 Gy. Lane 1 contained an
equivalent volume of 10 mM Tris-HCl and
1 mM EDTA, pH 8.0. Lane 7 contained
ATM, heterotrimeric RPA, and sonicated
calf thymus DNA (50 mg/ml). Lane 8 con-
tained ATM, RPA, sonicated DNA (50 mg/
ml), plus M13 plasmid DNA (20 mg/ml).
Only the portion of the autoradiogram
corresponding to RPA32 is shown.
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found previously for ATM in immunoprecipitation kinase as-
says (14, 15). Wortmannin is a relatively specific inhibitor of
the PI-3 kinase family, inhibiting the lipid kinase activity of
p110 PI-3 kinase at low nM levels (37) and DNA-PK kinase
activity with an IC50 of about 200 nM (13). In contrast, milli-
molar concentrations of wortmannin are required to inhibit
serine/threonine protein kinases that are more closely related
to the catalytic subunit of cAMP-dependent protein kinase (38).
These data argue against the presence of any contaminating
protein kinases in the ATM preparation.
Although DNA-PKcs and ATM are both members of the PI-3
kinase family of proteins, neither purified DNA-PKcs (13), im-
munoprecipitated ATM (14, 15), nor recombinant ATM (data
not shown) has detectable kinase activity toward phosphatidyl-
inositol. Likewise, we have not detected phosphatidylinositol
kinase activity for ATM purified by this procedure (data not
shown).
ATM was found not to bind to DNA-cellulose resin during the
purification procedure. The addition of calf thymus DNA did
not enhance the ATM-induced phosphorylation of PHAS-I, p53,
or Chk2 in vitro; however, a modest stimulation of phosphoryl-
ation of the 32-kDa subunit of recombinant RPA was observed
consistently with the addition of sheared calf thymus DNA. The
DNA binding properties of RPA have been assigned to the
70-kDa subunit (35). Because DNA appears to stimulate RPA
phosphorylation in the absence of the 70-kDa subunit, our
results suggest that either the recombinant 32- and 14-kDa
subunits of RPA have weak DNA binding properties them-
selves or that DNA enhances the activity of ATM toward
RPA32. However, because phosphorylation of other substrates
was not affected by DNA, this may be a property of RPA. A
previous study has shown that immunoprecipitates of ATM
phosphorylate RPA32 in a DNA-dependent manner (16). These
authors found that calf thymus DNA alone weakly enhanced
phosphorylation of RPA; however, the addition of single-
stranded closed circular M13 phage DNA together with calf
thymus DNA, significantly enhanced phosphorylation of
RPA32. Our results also show that, in the presence of calf
thymus DNA, M13 single-stranded closed circular DNA greatly
stimulated the ability of purified ATM to phosphorylate
RPA32. This property appeared to be specific for single-
stranded M13 circular DNA because other sheared calf thymus
DNA and irradiated plasmid DNA did not significantly en-
hance the phosphorylation of either PHAS-I or RPA by purified
ATM. M13 single-stranded closed circular DNA also supports
phosphorylation of RPA32 by DNA-PK (34). The authors of this
study speculated that secondary structure within the single-
stranded M13 DNA circle promoted phosphorylation of RPA32
by DNA-PK (34). It is possible therefore that phosphorylation
of RPA by ATM occurs in a similar manner.
The binding of DNA-PKcs to DNA is facilitated by the
Ku70/80 heterodimer. It is worth noting that Ku and DNA-
PKcs do not interact in the absence of DNA (39, 40) and that
the two proteins purify separately during biochemical purifica-
tion (7, 28, 30). It is therefore possible that ATM behaves in a
similar manner and that a protein partner that is required for
binding of ATM to DNA was removed during purification. Our
results show that Ku does not stimulate ATM kinase activity,
thus eliminating Ku as a DNA-targeting subunit for ATM. A
recent study has shown that in crude cell extracts, ATM binds
to DNA-cellulose that has been exposed to x-rays (17), raising
the possibility that either ATM is directly activated by binding
to damaged DNA or that ATM is recruited to damaged DNA by
another protein partner. We show that ionizing radiation-dam-
aged DNA does not activate the kinase activity of purified ATM
directly, consistent with the requirement of another protein
partner to target ATM to damaged DNA. Alternatively, binding
of ATM to damaged DNA may not affect its kinase activity. A
recent report has shown, using atomic force microscopy, that
ATM purified from HeLa cell nuclei binds ends of DNA (41).
The serine/threonine kinase activity of purified ATM is ab-
solutely dependent on manganese. Similar results were found
in ATM immunoprecipitation kinase assays (14, 15). The re-
quirement for manganese is unlikely to be caused by a peculi-
arity of the substrate used because phosphorylation of PHAS-I,
Chk2, RPA, and GST-p53 constructs by purified ATM all
FIG. 5. Phosphorylation by DNA-PK
in the presence of manganese. 0.5 mg
of recombinant PHAS-I, purified GST-p53
(amino acids 1–40), GST-Chk2 (amino ac-
ids 1–222), or His-tagged RPA (32- and
14-kDa subunits) was incubated with ei-
ther DNA-PKcs (0.06 mg) or DNA-PKcs
(0.06 mg) plus Ku (0.02 mg) in 20-ml reac-
tions that contained 50 mM Tris-HCl, pH
8.0, 100 mM KCl, 5% glycerol, 0.1 mM
EDTA, 0. 2 mM DTT, 250 mM ATP contain-
ing 2 mCi of [g-32P]ATP, and 10 mM MgCl2
or 10 mM MnCl2 as indicated. Where in-
dicated, samples also contained sonicated
calf thymus DNA at 10 mg/ml. Samples
were incubated for 5 min at 30 °C. Reac-
tions were stopped by the addition of SDS
sample buffer, and samples were ana-
lyzed on 15% SDS-polyacrylamide gels
followed by autoradiography overnight at
280 °C with intensifying screens.
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showed an absolute requirement for manganese. Significantly,
the p110 subunit of PI-3 kinase also shows manganese-depend-
ent serine/threonine kinase activity (42), suggesting that man-
ganese may be required for serine/threonine protein kinase
activity of all PI-3 kinase family members. Remarkably, the
protein kinase activity of DNA-PKcs toward several substrates
including PHAS-I, RPA32, and Chk2, was also stimulated by
manganese. Under the conditions used in these assays, DNA-
dependent phosphorylation of PHAS-I and RPA 32 by DNA-
PKcs in the presence of manganese was approximately equal to
that of DNA-PKcs plus Ku in the presence of magnesium,
suggesting that for these substrates, the presence of manga-
nese can bypass the need for Ku. However, manganese did not
support phosphorylation of hsp90 (28), various p53 GST fusion
proteins, or a synthetic peptide (26) derived from p53 by DNA-
PKcs (Fig. 5, and data not shown), suggesting that this effect
may also be substrate specific. The physiological relevance of
the requirement of ATM kinase activity for manganese is not
clear. It will be interesting to determine if the presence of
accessory proteins or factors alters the metal requirements of
ATM in the same way as observed here for DNA-PKcs.
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